Cui Xiaotian, Zhao Jinzhao, Zhou Xinda, Hua Ang, Chengxi, Tan Chen, and Han Wei Liu Ping, a 25-year-old living in Beijing, is queuing up outside the obesity clinic of the Peking University People’s Hospital early one morning, seeking a doctor’s prescription for the so-called “skinny jab” — a weight loss drug that has created a buying frenzy in China, where half the adults out of a total population of 1.4 billion are either overweight or obese.
Related Posts
We do a few things, but those few things must be the best in the world: Novo Nordisk’s top exec
Maziar Mike Doustdar, executive VP, Novo Nordisk; image credit: Company Synopsis Novo Nordisk, the most valuable pharmaceutical company in the…
Sun Pharma’s new drug to take on Pfizer, Eli Lilly is having a bad hair day.
Synopsis Last year, Sun Pharma infused over INR4,688 crore to buy US-based Concert Pharma. That deal gave it rights to…
Debt-hobbled Glenmark is looking to boost earnings. Execution will be key to winning back investors.
Glenn Saldanha, managing director and CEO, Glenmark pharmaceuticals; image credit: Agencies Synopsis Coping with a tough US generics business and…
